173 related articles for article (PubMed ID: 37606858)
1. [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
Seban RD; Arnaud E; Loirat D; Cabel L; Cottu P; Djerroudi L; Hescot S; Loap P; Bonneau C; Bidard FC; Huchet V; Jehanno N; Berenbaum A; Champion L; Buvat I
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4024-4035. PubMed ID: 37606858
[TBL] [Abstract][Full Text] [Related]
2. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Biard L; Lehmann-Che J; Teixeira L; Bouhidel FA; Poirot B; Bertheau P; Merlet P; Espié M; Resche-Rigon M; Sotiriou C; de Cremoux P
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1279-1288. PubMed ID: 29616304
[TBL] [Abstract][Full Text] [Related]
3. Role of
Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
[TBL] [Abstract][Full Text] [Related]
4. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
5. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
[TBL] [Abstract][Full Text] [Related]
6. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
[TBL] [Abstract][Full Text] [Related]
7. Additional value of
van Ramshorst MS; Teixeira SC; Koolen BB; Pengel KE; Gilhuijs KG; Wesseling J; Rodenhuis S; Valdés Olmos RA; Rutgers EJ; Vogel WV; Sonke GS; Vrancken Peeters MT
Cancer Imaging; 2017 May; 17(1):15. PubMed ID: 28545563
[TBL] [Abstract][Full Text] [Related]
8. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
Humbert O; Riedinger JM; Vrigneaud JM; Kanoun S; Dygai-Cochet I; Berriolo-Riedinger A; Toubeau M; Depardon E; Lassere M; Tisserand S; Fumoleau P; Brunotte F; Cochet A
J Nucl Med; 2016 Nov; 57(11):1707-1712. PubMed ID: 27103025
[TBL] [Abstract][Full Text] [Related]
10. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
[TBL] [Abstract][Full Text] [Related]
11. Utility of
Lee IH; Lee SJ; Lee J; Jung JH; Park HY; Jeong SY; Lee SW; Chae YS
BMC Cancer; 2020 Nov; 20(1):1106. PubMed ID: 33198673
[TBL] [Abstract][Full Text] [Related]
12. Clinical Utility of Pre-Therapeutic [18F]FDG PET/CT Imaging for Predicting Outcomes in Breast Cancer.
Najid S; Seban RD; Champion L; De Moura A; Sebbag C; Salaün H; Cabel L; Bonneau C
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685551
[TBL] [Abstract][Full Text] [Related]
13. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
14. [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.
Raccagni I; Belloli S; Valtorta S; Stefano A; Presotto L; Pascali C; Bogni A; Tortoreto M; Zaffaroni N; Daidone MG; Russo G; Bombardieri E; Moresco RM
PLoS One; 2018; 13(5):e0197754. PubMed ID: 29791503
[TBL] [Abstract][Full Text] [Related]
15. Combination of breast imaging parameters obtained from
Grapin M; Coutant C; Riedinger JM; Ladoire S; Brunotte F; Cochet A; Humbert O
Eur J Radiol; 2019 Apr; 113():81-88. PubMed ID: 30927964
[TBL] [Abstract][Full Text] [Related]
16. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
17. Prognostic utility of FDG PET/CT in advanced ovarian, fallopian and primary peritoneal high-grade serous cancer patients before and after neoadjuvant chemotherapy.
Watanabe M; Nakamoto Y; Ishimori T; Saga T; Kido A; Hamanishi J; Hamanaka Y; Togashi K
Ann Nucl Med; 2020 Feb; 34(2):128-135. PubMed ID: 31768818
[TBL] [Abstract][Full Text] [Related]
18. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Humbert O; Riedinger JM; Charon-Barra C; Berriolo-Riedinger A; Desmoulins I; Lorgis V; Kanoun S; Coutant C; Fumoleau P; Cochet A; Brunotte F
Clin Cancer Res; 2015 Dec; 21(24):5460-8. PubMed ID: 26130460
[TBL] [Abstract][Full Text] [Related]
19. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
20. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):32-40. PubMed ID: 23929431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
